News & Updates

Antibiotic and antiviral therapy in COVID-19 patients: Updates from ESCMID Global 2024

In COVID-19 patients, antibiotic therapy should be reserved only for suspected bacterial superinfections.

However, international data from over 1 million hospitalized COVID-19 patients across 65 countries showed that antibiotics were commonly prescribed empirically despite the low rates of reported bacterial co-infection.¹

Novel cardiac myosin inhibitor helps with exercise capacity in obstructive HCM

Treatment with the oral selective cardiac myosin inhibitor aficamten produced improvements in peak oxygen uptake in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), as shown in the phase III SEQUOIA-HCM trial.

Chronic fatigue syndrome is challenging to diagnose

Patients with chronic fatigue syndrome (CFS) constantly experience extreme tiredness despite sleeping well and drinking a lot of coffee.

VTE recurrence in chronic thromboembolic pulmonary hypertension higher with DOACs vs warfarin

For patients with chronic thromboembolic pulmonary hypertension (CTEPH) receiving anticoagulation treatment, direct oral anticoagulants (DOACs) appear to yield similar survival and bleeding outcomes but higher risk of venous thromboembolism (VTE) recurrence compared with warfarin, according to a study.

ctDNA EGFRm helps pinpoint who benefits from 1L osimertinib-chemo combo

Detectable EGFRm in plasma ctDNA prior to treatment may define a subgroup of patients with advanced EGFRm NSCLC who would derive the most benefit from the addition of chemo to 1L osimertinib, according to an exploratory analysis of FLAURA2 presented at AACR 2024